Alimera Sciences — Investor Day (March 2015)
67 slides from Alimera Sciences's investor day presentation, Mar 25, 2015
Slide 1: Analyst Day March 25, 2015
hh SCIENCES! LOOK FORWARD. Analyst Day March 25, 2015
Slide 2: Dan Myers, President and CEO
SCIENCES LOOK FORWARD. Dan Myers, President and CEO
Slide 3: Forward-Looking Statement
3 Forward-Looking Statement This presentation contains "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1 995, regarding, among other things, the marketing approval and commercialization of ILUVIEN in the United States and European Unio n. Such forw
Slide 4: Agenda
4 Agenda • Introduction – Dan Myers • U.S. Indication – Ken Green • Understanding Intraocular Pressure – Dr. Tom Mundorf • U.S. Experience – Dr. Alex Eaton • Q and A with Physicians • Commercial Opportunity – Dave Holland • Economics – Rick Eiswirth • Closing Q and A
Slide 5: ILUVIEN Overview, Applicator and Implant
5 ILUVIEN Overview ILUVIEN Applicator ILUVIEN Implant
Slide 6: ILUVIEN Procedure
6 ILUVIEN Procedure • Standard intravitreal injection with a 25-gauge needle – Conducted in the physician’s office – Minimal training required – Allows for a self-sealing wound • Non-bioerodible implant is made of polyimide, the same material used for many IOLs
Slide 7: Ken Green PhD, CSO
hh SCIENCES! LOOK FORWARD. Ken Green PhD. , CSO
Slide 8: Important Safety Information
8 Important Safety Information Contraindications • ILUVIEN is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicell
Slide 9: Important Safety Information
9 Important Safety Information • ILUVIEN is a non-bioerodable intravitreal implant in a drug delivery system containing 0.19 mg fluocinolone acetonide, designed to release fluocinolone acetonide at an initial rate of 0.25 μg/day and lasting 36 months. • The efficacy of ILUVIEN was assessed in two th
Slide 10: ILUVIEN Safety Data
10 ILUVIEN Safety Data Patients (study eye), % Control (n = 121) 0.2 µg/d FAc (ILUVIEN) (n = 235) Cataract considered an AEa 50 82 Cataract extraction performeda 27 80 ILUVIEN (N = 375) n (%) Control (N = 185) n (%) IOP elevation ≥ 10 mm Hg from baseline 127 (34) 18 (10) IOP elevation ≥ 30 mm Hg 75
Slide 11: Broader U.S. Label
11 Broader U.S. Label For the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure United States Europe For the treatment of vision impairment in patients with chronic DME, considered ins
Slide 12: Understanding Steroid Induced Elevated Intraocular Pressure
Understanding Steroid Induced Elevated Intraocular Pressure Thomas Mundorf, MD Mundorf Eye Center, Charlotte, North Carolina
Slide 13: Eye Anatomy Cross Section
Eye Anatomy Cross Section
Slide 14: Eye Anatomy
Eye Anatomy The Angle cinany
Slide 15: Eye Anatomy
Eye Anatomy Orne ibriform layer Aqueous Flow
Slide 16: Glaucoma vs Steroid Induced Ocular Hypertension
Glaucoma vs Steroid Induced Ocular Hypertension Glaucoma (nerve damage) Ocular Hypertension (high pressure)
Slide 17: Cupping Associated With Glaucoma
Cupping Associated With Glaucoma
Slide 18: Treatments for Elevated Intraocular Pressure
Treatments for Elevated Intraocular Pressure
Slide 19: Laser Trabeculoplasty
Laser Trabeculoplasty Laser energy to trabecular meshwork Increases outflow facility Non-invasive procedure Indications Elevated IOP Effective IOP reduction for Primary open angle glaucoma Pigmentary glaucoma Pseudoexfoliation glaucoma Steroid induced
Slide 20: Trabeculectomy
Trabeculectomy • Glaucoma drainage devices create an alternate aqueous pathway from the eye’s anterior chamber by channeling aqueous humor out of the eye through a tube to a sub-conjunctival bleb
Slide 21: Tube Shunt
Tube Shunt Trabeculectomies (trabs) tend to do well in patients who have had steroid implants
Slide 22: Understanding the Indication
Understanding the Indication
Slide 23: FDA Indication
FDA Indication • ILUVIEN is indicated for the treatment of diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. ILUVIEN Package Insert. Alpharetta, GA; Alimera Sciences, Inc.; 2014
Slide 24: Did patients previously treated with corticosteroids need IOP-lowering surgery?
Did patients in the study previously treated with a course of corticosteroids need IOP- lowering surgery?
Slide 25: FAME Inclusion/Exclusion Criteria
FAME Inclusion/Exclusion Criteria • IOP Related Exclusion • Patients with a history of uncontrolled IOP elevation with steroid use that did not respond to topical therapy were excluded from participation History of Prior Intravitreal Steroid Use Prior Steroid Treatment No Prior Steroid Treatment 0.2
Slide 26: A Glaucoma Specialist's Perspective
A Glaucoma Specialist’s Perspective • Most patients treated with ILUVIEN do not develop elevated IOP (62% vs. 38%) • Most patients treated with ILUVIEN that do develop elevated IOP, are treatable with non-invasive therapies: • Topical drops • Laser trabeculoplasty • Based on the approved indication,
Slide 27: Retina & Glaucoma: Working Together
Retina & Glaucoma Working Together: Glaucoma Specialist/Retinal Surgeon Cooperation Communication is vital to successful patient care.
Slide 28: US ILUVIEN Experience
US ILUVIEN Experience Alexander M Eaton, M.D. Retina Health Center, Ft. Myers, Florida
Slide 29: My Initial Understanding of the Technology
My Initial Understanding of the Technology • ILUVIEN was equivalent to an Ozurdex® implant with a 3 year half life • Treatment would be needed every few years • There was a significant risk of glaucoma and that 5% of patients would require glaucoma surgery • Phakic patients would require surgery wit
Slide 30: Delivery Characteristics
Delivery Characteristics • Having an intraocular implant that continuously delivers daily, submicrogram levels of a steroid for 36 months is a differentiated way to manage these patients
Slide 31: Delivery Characteristics
Delivery Characteristics Rabbit Monkey Pharmacokinetics and Pharmacodynamics of a Sustained-Release Dexamethasone Intravitreal Implant. Joan-En Chang-Lin et al, Investigative Ophthalmology & Visual Science, January 2011, Vol. 52, No. 1 Ocular Pharmacokinetics of Fluocinolone Acetonide Following Iluv
Slide 32: Pressure Response
Pressure Response • We learned from the FAME study that by selecting only patients without a significant prior steroid response, the risk of requiring glaucoma surgery is reduced. • In the FAME study none of the patients in this group required glaucoma surgery. • Another publication has reported sim
Slide 33: What About The Device?
What About The Device? • Prior to using the device I had been concerned about the non-bio erodible nature of the implant • I worried that patients who require 2 or more implants during their life span would see them floating around their eye. • What I have learned is: 1. The ILUVIEN implant is much
Slide 34: ILUVIEN vs Ozurdex Size Comparison
ILUVIEN vs Ozurdex Size Comparison In millimeters
Slide 35: DME Patients in General
DME Patients in General • DME patients have many co-morbidities and require frequent doctor visits and treatments. • On average, they have 25 doctor visits per year.* • Patients prefer less injections when given the option. *Kiss S, et al. Clinical Ophthalmology 2014:8 1611-1621
Slide 36: Learning Curve
Learning Curve • Now we can implant this device and provide continuous multi- year delivery (36 months). • Unlike other therapies that last for 1-3 months at best, this therapy can be given once (every 36 months) and is an appropriate baseline therapy. • As in the study, if additional short acting t
Slide 37: How I Approach Patients with DME
How I Approach Patients with DME • Subdivide into groups • New Patients • No history of stroke • Start with VEGF inhibitor +/- Laser • If pseudophakic and recurrent or incomplete clearing of the edema • If no history of rise in IOP with Steroids -> Review benefits of ILUVIEN and get BI Check and I h
Slide 38: Case #1
Case #1 • 79 YO W M • DME since 2002 • S/P Multiple Treatments • Triamcinolone • Focal Laser • Avastin • Lucentis • Recurrent DME
Slide 39: Case – Patient #1
Case – Patient #1 • 1/5/2015 • VA 20/200 • OCT • Decision made for treatment • BI Done • 1/26/15 • ILUVIEN Treatment • 2/16/15 3/17/15 • VA 20/100 VA 20/80
Slide 40: Case #2
Case #2 • 73 YO WF • DME since 2008 • S/P Multiple Treatments • Focal Laser • Lucentis • Triamcinolone • Recurrent DME
Slide 41: Case #2
Case #2 GODINO, Richard • 2/6/15 • VA 20/50 • ILUVIEN Treatment • 2/16/15 • Edema Cleared • VA 20/50 • 3/10/15 (Phone Call) • Reports when reading, she can now see little numbers such as numbers on business cards • Wants to know when her other eye can be treated
Slide 42: Case #3
Case #3 • 75 YO WM • DME since 2007 • S/P Multiple Treatments • Focal Laser • Avastin • Lucentis • Triamcinolone • Recurrent DME
Slide 43: 1/31/14 S/P Lucentis Monthly x 20/40 1/9/15 S/P Eylea 12/1/14 20/40 2/6/15 S/P ILUVIEN
1/31/14 S/P Lucentis Monthly x 2 20/40 1/9/15 S/P Eylea 12/1/14 20/40 2/6/15 S/P ILUVIEN 1/23/15 20/80 2/13/15 S/P ILUVIEN 1/23/15 S/P Lucentis 2/6/15 20/40 1/23/15 ILUVIEN 20/50
Slide 44: 3/13/14 S/P ILUVIEN 1/23/15 S/P Lucentis 2/6/15 20/25 – best VA since 2/17/12
3/13/14 S/P ILUVIEN 1/23/15 S/P Lucentis 2/6/15 20/25 – best VA since 2/17/12
Slide 45: Case #3
Case #3 • Good example of using ILUVIEN as the baseline treatment • Patient did not respond completely to VEGF inhibitors in the past • Patient did not respond to one treatment • Satisfactory outcome achieved with multiple therapies
Slide 46: Insurance
Insurance • Pre-Authorization requirements by commercial and Medicare replacement plans have increased and have changed over the last 6 months. • If our office misses that a pre-authorization is required, and a patient is treated, we have to write off the cost of the medication. • Because Alimera ha
Slide 47: Patient Population
Patient Population - How many patients are candidates for treatment in our practice? • Over the time period from January 7 to March 20th, we identified 59 patients for treatment and benefits investigations were performed. • 51 of 59 are Medicare/Medicare Advantage • The results of the benefits inves
Slide 48: Patient Response
Patient Response • Very positive. • They are tired of frequent injections. • To date, steroid induced pressure elevation has not been a problem. • One of the few times a patient has given me a bear hug after treatment.
Slide 49: Patient Video
Patient Video
Slide 50: Summary
Summary • Many of my pre-conceived notions about ILUVIEN were incorrect. • Its small size, propensity to position itself out of the visual pathway, and favorable risk profile in patients who have not had a significant pressure elevation to a prior steroid challenge, have changed my perspective on th
Slide 51: Q and A March 2015
hh SCIENCES 7 LOOK FORWARD. OandA March 2015
Slide 52: A Large Commercial Opportunity
Dan Myers, President and CEO A Large Commercial Opportunity
Slide 53: Commercial Highlights
53 Commercial Highlights ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19mg is the only multi-year sustained delivery corticosteroid approved for diabetic macular edema FDA approval of ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19mg received in September 2014 Commerciall
Slide 54: Global Commercialization Status
54 Global Commercialization Status France Spain Portugal Italy Ireland U.K. Germany Poland Belgium Denmark Netherlands Austria Marketed Approved Approval Pending U.S. CR Luxembourg
Slide 55: A Large Commercial Opportunity
Dave Holland, SVP Sales and Marketing A Large Commercial Opportunity
Slide 56: DME Prevalence / Incidence in the U.S.
56 2015 2019 575,000 646,000 DME Prevalence / Incidence in the U.S. Existing DME Patients Incidence Clinically Significant DME Prevalence Source: Third party market research. (a) KANTAR market research. (b) 40+ age estimated for 2015 • 575,000 DME patients with vision threatening symptoms (a,b) • In
Slide 57: DME Competitive Landscape in U.S.
57 DME Competitive Landscape in U.S. Steroids Anti-VEGF Ozurdex Eylea Lucentis Avastin DME Approved* X (Used Off-Label) DME Approval Date Sept. 2014 June 2014 July 2014 Aug. 2012 N/A Delivery Duration Up to 36 Months ~3–5 Months ~1–2 Months ~1–2 Months ~1–2 Months Common Side Eff cts Catarac
Slide 58: Current SOC for DME is Insufficient
58 Current SOC for DME is Insufficient • U.S. and European Pivotal Trials for Lucentis − ~40-50% of patients did not achieve 20/40 outcome(a) • DRCR.net(b) Protocol I − >50% of ranibizumab-treated eyes did not achieve a 2 or more line improvement in visual acuity from baseline at 2 years. − >40% of
Slide 59: Current SOC for DME is Insufficient
59 Current SOC for DME is Insufficient Patients Achieving BCVA Levels Long Term (2 or More Years) BCVA 20/20, 15.0% BCVA 20/40, 31.6% BCVA 20/60 24.3% BCVA 20/80 16.4% BCVA 20/100 12.6% Source: ASI MR June 2014 ~55% of patients end up 20/60 or worse
Slide 60: Estimate of Population that Tolerates Corticosteroids
60 Estimate of Population that Tolerates Corticosteroids Kantar Health Epidemiology Review Study 2011 (a) Estimate based on average % of patients not requiring IOP medication • Majority of patients receiving an intravitreal corticosteroid do not require IOP lowering medication − FAME Study – 62% vs
Slide 61: Creating A Shift in Treatment Paradigm
61 Creating A Shift in Treatment Paradigm Current Therapy Allocation Projected Therapy Allocation with ILUVIEN Proprietary market research by SciMedica Group 37.9% 35.5% 1.9% 5.6% 1.2% 15.4% 2.0% 1.7% Avastin Lucentis Ozurdex Triamcinolone (IVTA) Eylea Laser Photocoagulation Vitrectomy Other 30.3% 2
Slide 62: U.S. Commercialization Team
62 U.S. Commercialization Team • Senior sales and marketing team with significant retinal launch experience − (Visudyne®, Macugen®, Lucentis®, Ozurdex®, Jetrea®) • Four regions, 32 experienced sales representatives • Targeting ~2,500 retina specialists
Slide 63: Economics
Rick Eiswirth, COO and CFO Economics
Slide 64: U.S. Reimbursement Strategy
64 U.S. Reimbursement Strategy • Significant unmet need, clinical profile and pharmaco-economic benefit supports broad access − Substantially less budget impact than 3 years of short acting, anti-VEGF therapy • FDA indication positions ILUVIEN as a direct alternative to Anti-VEGF therapies currently
Slide 65: Adjudication is the Issue, Coverage is Not
65 Adjudication is the Issue, Coverage is Not • No specific J-code in 2015 affects reimbursement timing • Alimera is providing extensive support to the practices − AccessPlus • Reimbursement support • Patient financial assistance • Product acquisition flexibility − Team of field-based reimbursement
Slide 66: Strong Economics in the U.S.
66 Ozurdex Eylea Lucentis Avastin Annual Labeled Injections Every 3 years 3 – 4 4 – 6 4 – 6 ~4 – 6 Cost of Injection $8,800 $1,300 $1,850 $1,170 $50 1st Year Cost(a) $8,800 $3,250 $9,250 $5,850 $250 3-Year Cost(a) $8,800 $9,750 $27,750 $17,550 $750 Strong Economics in the U.S. Competitive Landscape
Slide 67: Q and A March 2015
hh SCIENCES 7 LOOK FORWARD. OandA March 2015